UY33942A - Derivados tópicos de piridil/pirazinil metilenoxi como inhibidores de la tirosina cinasa del bazo - Google Patents

Derivados tópicos de piridil/pirazinil metilenoxi como inhibidores de la tirosina cinasa del bazo

Info

Publication number
UY33942A
UY33942A UY0001033942A UY33942A UY33942A UY 33942 A UY33942 A UY 33942A UY 0001033942 A UY0001033942 A UY 0001033942A UY 33942 A UY33942 A UY 33942A UY 33942 A UY33942 A UY 33942A
Authority
UY
Uruguay
Prior art keywords
typosin
pirazinil
methylenoxi
cinasa
piridil
Prior art date
Application number
UY0001033942A
Other languages
English (en)
Inventor
Michael David Barker
Liddle John
David Matthew Wilson
Francis Louis Atkinson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of UY33942A publication Critical patent/UY33942A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de la fórmula I, o una de sus sales; que es un inhibidor de la tirosina cinasa del bazo (SYK) y por tanto de uso potencial en el tratamiento de las enfermedades que resultan de la activación inapropiada de las células cebadas, macrófago s, y células B y las respuestas inflamatorias y daño de tejidos relacionados, por ejemplo las enfermedades inflamatorias y/o afecciones alérgicas, en la terapia del cáncer, específicamente en neoplasias malignas tipo hemo, y en las enfermedades autoinmunes.
UY0001033942A 2011-03-11 2012-03-08 Derivados tópicos de piridil/pirazinil metilenoxi como inhibidores de la tirosina cinasa del bazo UY33942A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1104153.0A GB201104153D0 (en) 2011-03-11 2011-03-11 Novel compounds

Publications (1)

Publication Number Publication Date
UY33942A true UY33942A (es) 2012-09-28

Family

ID=43980841

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033942A UY33942A (es) 2011-03-11 2012-03-08 Derivados tópicos de piridil/pirazinil metilenoxi como inhibidores de la tirosina cinasa del bazo

Country Status (41)

Country Link
US (4) US8993560B2 (es)
EP (2) EP2683709B1 (es)
JP (1) JP5902206B2 (es)
KR (1) KR101564007B1 (es)
CN (1) CN103502239B (es)
AR (1) AR085711A1 (es)
AU (1) AU2012228439C1 (es)
BR (1) BR112013022784A2 (es)
CA (1) CA2828518C (es)
CL (1) CL2013002602A1 (es)
CO (1) CO6791612A2 (es)
CR (1) CR20130459A (es)
CY (2) CY1116569T1 (es)
DK (2) DK2937344T3 (es)
DO (1) DOP2013000207A (es)
EA (1) EA022437B1 (es)
ES (2) ES2541530T3 (es)
GB (1) GB201104153D0 (es)
HK (2) HK1192887A1 (es)
HR (2) HRP20150752T1 (es)
HU (2) HUE035443T2 (es)
IL (1) IL227873A (es)
JO (1) JO3072B1 (es)
LT (1) LT2937344T (es)
MA (1) MA35030B1 (es)
ME (2) ME02167B (es)
MX (1) MX339123B (es)
MY (1) MY169314A (es)
NO (1) NO2937344T3 (es)
PE (1) PE20140998A1 (es)
PL (2) PL2937344T3 (es)
PT (2) PT2937344T (es)
RS (2) RS54120B1 (es)
SG (1) SG193015A1 (es)
SI (2) SI2937344T1 (es)
SM (1) SMT201500188B (es)
TW (1) TWI527806B (es)
UA (1) UA109807C2 (es)
UY (1) UY33942A (es)
WO (1) WO2012123311A1 (es)
ZA (1) ZA201306554B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014081616A1 (en) * 2012-11-21 2014-05-30 Merck Sharp & Dohme Corp. Preparation of precursors for leukotriene antagonists
ES2781332T3 (es) * 2015-07-24 2020-09-01 Glaxo Group Ltd Tratamiento para el vitíligo
EP3665171A1 (en) 2017-10-19 2020-06-17 Bayer Animal Health GmbH Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP3958851B1 (en) * 2019-04-23 2024-08-14 The Cleveland Clinic Foundation Allosteric activators of the alpha ia-adrenergic receptor
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN113340965B (zh) * 2020-03-03 2022-12-16 北京中医药大学 一种用于检测扑尔敏用途的人工智能生物传感器检测方法

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335121A (en) 1980-02-15 1982-06-15 Glaxo Group Limited Androstane carbothioates
AU570439B2 (en) 1983-03-28 1988-03-17 Compression Labs, Inc. A combined intraframe and interframe transform coding system
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
US5552438A (en) 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
IL108630A0 (en) * 1993-02-18 1994-05-30 Fmc Corp Insecticidal substituted 2,4-diaminoquinazolines
US5426196A (en) 1993-12-22 1995-06-20 Glaxo Inc. Synthesis of diaryl methanes
ATE191470T1 (de) 1994-06-15 2000-04-15 Wellcome Found Enzymhemmer
CA2245586A1 (en) 1996-02-06 1997-08-14 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
WO1998050031A1 (en) 1997-05-07 1998-11-12 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
DE19723722A1 (de) 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
WO1999016766A1 (fr) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Derives de benzodioxole
WO1999018096A1 (en) 1997-10-02 1999-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
JP4135318B2 (ja) 1997-12-15 2008-08-20 アステラス製薬株式会社 新規なピリミジン−５−カルボキサミド誘導体
CA2317439A1 (en) 1998-01-14 1999-07-22 Wayne J. Brouillette Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
EP1070056B1 (en) 1998-03-14 2004-06-30 ALTANA Pharma AG Phthalazinone pde iii/iv inhibitors
JP2002516305A (ja) 1998-05-12 2002-06-04 アメリカン・ホーム・プロダクツ・コーポレイション インスリン抵抗性および高血糖症の治療に有用な２，３，５−置換ビフェニル
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
CA2362401A1 (en) 1999-02-04 2000-08-10 Paul Fleming G-protein coupled heptahelical receptor binding compounds and methods of use thereof
AU4501800A (en) 1999-05-04 2000-11-17 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
EP1178963A1 (en) 1999-05-12 2002-02-13 Neurosearch A/S Ion channel modulating agents
IL147281A0 (en) 1999-06-29 2002-08-14 Uab Research Foundation Methods of treating fungal infections with inhibitors of nad synthetase enzyme
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CO5180649A1 (es) 1999-09-01 2002-07-30 Abbott Lab Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
MXPA02009763A (es) 2000-04-04 2003-03-27 Shionogi & Co Composiciones aceitosas las cuales contienen farmacos altamente solubles en grasa.
AU2001244610A1 (en) 2000-04-05 2001-10-23 Shionogi And Co., Ltd. Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof
CO5310534A1 (es) 2000-08-05 2003-08-29 Glaxo Group Ltd Nuevos derivados de androstano anti-inflamatorios
PL362711A1 (en) 2000-09-29 2004-11-02 Glaxo Group Limited Morpholin-acetamide derivatives for the treatment of inflammatory diseases
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
US6484903B2 (en) 2001-01-09 2002-11-26 Riverwood International Corporation Carton with an improved dispensing feature in combination with a unique handle
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ATE365720T1 (de) 2001-03-08 2007-07-15 Glaxo Group Ltd Agonisten von beta-adrenorezeptoren
DE60224172T2 (de) 2001-03-22 2008-12-04 Glaxo Group Ltd., Greenford Formanilid-derivative als beta2-adrenorezeptor-agonisten
ES2314052T3 (es) 2001-04-30 2009-03-16 Glaxo Group Limited Derivados de ester de 17beta-carbotioato de androstano con un grupo ester ciclico en la posicion 17alfa.
US20040248867A1 (en) 2001-06-12 2004-12-09 Keith Biggadike Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives
WO2003006628A2 (en) 2001-07-13 2003-01-23 Virtual Drug Development, Inc. Nad synthetase inhibitors and uses thereof
CA2458534C (en) 2001-09-14 2011-11-01 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
AU2002226401A1 (en) 2001-12-11 2003-06-23 Rhodia Chimie Catalytic pgm mixture for hydrosilylation
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US20030158195A1 (en) 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
EP1467982B8 (en) 2002-01-14 2007-04-11 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them, and uses thereof
EP1467730A4 (en) 2002-01-22 2010-03-10 Univ California Non-steroid ligands for the glucocorticoid receptor, compositions and uses thereof
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
DK1490062T3 (da) 2002-03-26 2008-04-28 Boehringer Ingelheim Pharma Glukokortikoidmimetika, fremgangsmåder til fremstilling deraf, farmaceutiske sammensætninger og anvendelser deraf
WO2003082787A1 (en) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
CA2481320A1 (en) 2002-04-11 2003-10-23 Merck & Co., Inc. 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
JP2005523920A (ja) 2002-04-25 2005-08-11 グラクソ　グループ　リミテッド フェネタノールアミン誘導体
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
AU2003281355A1 (en) 2002-07-08 2004-01-23 Pfizer Products Inc. Modulators of the glucocorticoid receptor
PL375442A1 (en) 2002-07-18 2005-11-28 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
CA2496175A1 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
MXPA05002887A (es) 2002-09-16 2005-05-27 Glaxo Group Ltd Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibidores de fosfodiesterasa.
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
AU2003270783C1 (en) 2002-09-20 2010-05-20 Merck Sharp & Dohme Corp. Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
US20070020253A1 (en) 2002-10-16 2007-01-25 David Williams Spleen tyrosine kinase catalytic domain:crystal structure and binding pockets thereof
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
JP2006506373A (ja) 2002-10-22 2006-02-23 グラクソ　グループ　リミテッド 医薬アリールエタノールアミン化合物
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
EP1556342B1 (en) 2002-10-28 2008-03-26 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
EP1572215B1 (en) 2002-12-20 2009-09-02 Glaxo Group Limited Benzo[d]azepine derivatives for the treatment of neurological disorders
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
CN101031539A (zh) * 2003-08-14 2007-09-05 旭化成制药株式会社 取代的芳基链烷酸衍生物及其用途
BRPI0416128B8 (pt) 2003-11-03 2021-06-22 Glaxo Group Ltd dispositivo de dispensação de fluido
JP2005170939A (ja) 2003-11-20 2005-06-30 Takeda Chem Ind Ltd 糖尿病の予防・治療剤
EP1737809B1 (en) 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
WO2005086904A2 (en) 2004-03-08 2005-09-22 Amgen Inc. Therapeutic modulation of ppar (gamma) activity
WO2006000398A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators
WO2006000401A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited Substituted oxazines as glucocorticoid receptor modulators
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
CA2584318A1 (en) 2004-10-19 2006-05-04 F. Hoffmann-La Roche Ag Quinoline derivatives
ATE517908T1 (de) 2005-01-10 2011-08-15 Glaxo Group Ltd Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
US20090124588A1 (en) 2005-01-10 2009-05-14 Glaxo Group Limited Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions
SG159528A1 (en) 2005-02-04 2010-03-30 Senomyx Inc Compounds comprising linked hetero aryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
JP2008535884A (ja) 2005-04-14 2008-09-04 グラクソ グループ リミテッド グルココルチコイド受容体リガンドとしてのインダゾール
GB0513297D0 (en) 2005-06-29 2005-08-03 Glaxo Group Ltd Novel compounds
WO2007009681A1 (en) 2005-07-15 2007-01-25 Glaxo Group Limited 1 , 1-DIOXID0-2 , 3-DIHYDRO-l , 2-BENZISOTHIAZ0L-6-YL-1H-INDAZOL-4-YL-2 , 4-PYRIMIDINEDI AMINE DERIVATIVES
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
WO2007033002A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
US20070225285A1 (en) 2005-11-04 2007-09-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070104620A1 (en) 2005-11-07 2007-05-10 Bilal Zuberi Catalytic Exhaust Device
GB0522880D0 (en) 2005-11-09 2005-12-21 Glaxo Group Ltd Novel compounds
AU2007292816B2 (en) 2006-09-07 2011-11-17 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
WO2008046216A1 (en) 2006-10-18 2008-04-24 Methylgene, Inc. Kinase inhibitors and uses thereof
AU2007321719B2 (en) 2006-11-15 2013-11-21 Ym Biosciences Australia Pty Ltd Inhibitors of kinase activity
WO2008079277A1 (en) 2006-12-22 2008-07-03 Millennium Pharmaceuticals, Inc. Certain pyrazoline derivatives with kinase inhibitory activity
TW201006090A (en) 2008-07-16 2010-02-01 Chien-Chiang Chan Applied structure of energy storage device
EP2313406B1 (de) * 2008-08-05 2015-02-25 Boehringer Ingelheim International GmbH 4-dimethylaminophenyl-substituierte napththyridine und ihre verwendung als arzneimittel
CA2731477A1 (en) 2008-08-05 2010-02-11 Nicox S.A. New no releasing steroids derivatives
GB0910691D0 (en) 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
CA2780128A1 (en) 2009-11-06 2011-05-12 P. Jeffrey Conn Aryl and heteroaryl sulfones as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction

Also Published As

Publication number Publication date
AR085711A1 (es) 2013-10-23
IL227873A0 (en) 2013-09-30
PL2683709T3 (pl) 2015-10-30
CN103502239A (zh) 2014-01-08
TWI527806B (zh) 2016-04-01
MY169314A (en) 2019-03-21
NO2937344T3 (es) 2018-01-20
ME02167B (me) 2015-10-20
JP5902206B2 (ja) 2016-04-13
CA2828518C (en) 2019-06-18
IL227873A (en) 2016-02-29
PT2683709E (pt) 2015-09-15
CN103502239B (zh) 2015-07-01
EP2937344B1 (en) 2017-08-23
PT2937344T (pt) 2017-10-09
ES2641483T3 (es) 2017-11-10
CL2013002602A1 (es) 2014-03-28
EA201391165A1 (ru) 2014-03-31
JP2014507457A (ja) 2014-03-27
AU2012228439A1 (en) 2013-05-02
KR20130143716A (ko) 2013-12-31
UA109807C2 (xx) 2015-10-12
US20120232061A1 (en) 2012-09-13
ES2541530T3 (es) 2015-07-21
SI2683709T1 (sl) 2015-08-31
US20140005177A1 (en) 2014-01-02
GB201104153D0 (en) 2011-04-27
DK2937344T3 (en) 2017-10-23
MX2013010373A (es) 2013-10-30
JO3072B1 (ar) 2017-03-15
US8993560B2 (en) 2015-03-31
AU2012228439B2 (en) 2015-11-26
EP2683709B1 (en) 2015-05-06
DOP2013000207A (es) 2014-04-30
BR112013022784A2 (pt) 2016-12-06
MA35030B1 (fr) 2014-04-03
CA2828518A1 (en) 2012-09-20
RS56719B1 (sr) 2018-03-30
US20160355505A1 (en) 2016-12-08
HK1192887A1 (en) 2014-09-05
SI2937344T1 (sl) 2017-11-30
CY1116569T1 (el) 2017-03-15
HUE026541T2 (en) 2016-06-28
TW201249825A (en) 2012-12-16
CY1119581T1 (el) 2018-03-07
PL2937344T3 (pl) 2018-01-31
HRP20150752T1 (en) 2015-08-14
KR101564007B1 (ko) 2015-10-28
EP2937344A1 (en) 2015-10-28
CO6791612A2 (es) 2013-11-14
WO2012123311A1 (en) 2012-09-20
HRP20171647T1 (hr) 2017-12-15
CR20130459A (es) 2014-02-04
LT2937344T (lt) 2017-11-10
AU2012228439C1 (en) 2016-11-03
HK1216751A1 (zh) 2016-12-02
HUE035443T2 (en) 2018-05-02
ME02872B (me) 2018-04-20
DK2683709T3 (en) 2015-08-03
PE20140998A1 (es) 2014-09-04
NZ614199A (en) 2015-10-30
MX339123B (es) 2016-05-12
SMT201500188B (it) 2015-09-07
US9447074B2 (en) 2016-09-20
ZA201306554B (en) 2017-05-31
SG193015A1 (en) 2013-10-30
EP2683709A1 (en) 2014-01-15
RS54120B1 (en) 2015-12-31
EA022437B1 (ru) 2015-12-30
US20150166508A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
UY33942A (es) Derivados tópicos de piridil/pirazinil metilenoxi como inhibidores de la tirosina cinasa del bazo
CR20150633A (es) Derivados del bipirazol como inhibidores jak
CU24335B1 (es) Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer
UY33359A (es) Inhibidores de la triosina de bazo (syk) y sus metodos de preparacion
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
GT201600123A (es) Inhibidores de syk
UY32585A (es) Nuevos derivados del indazol utiles como inhibidores de la familia fosfoinositida 3´oh quinasa
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
GT200600394A (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis.
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
BR112017003312A2 (pt) compostos de indazol como inibidores de fgfr quinase, preparação e uso dos mesmos
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
BR112014005226A2 (pt) derivados de benzonitrila como inibidores de cinase
UY35633A (es) Inhibidores de bromodominios
CO6670585A2 (es) Promotores de apotosis n-acilsufonamidas
GT201300320A (es) Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer.
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
UY34132A (es) Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab.
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
UY33885A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
BR112016001645A8 (pt) derivados de oxoquinazolinil-butanamida, seu uso, medicamentos e kit
BR112013029999A2 (pt) derivados de tiazol
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
PE20151494A1 (es) Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210804